# BioTrace Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biotrace-medical

- Industry: Medical Devices & Equipment
- Headquarters: Menlo Park, US
- Website: www.biotracemedical.com
- Total disclosed funding: $3.5M
- Latest round: Series A (Feb 14, 2014)
- Investors on record: 1

## About

BioTrace Medical Inc. develops innovative cardiovascular solutions, focusing on its flagship product, the Tempo® Temporary Pacing Lead, designed for advanced cardiac procedures to enhance patient safety and recovery.Founded in 2013, BioTrace Medical Inc. is headquartered in Menlo Park, US, and specializes in temporary pacing solutions for cardiac procedures. The company has successfully completed 2 funding rounds, with the most recent being a Series B round in March 2021, raising USD 10.87 mn, which matches the total amount raised of USD 10.87 mn. The current company valuation is USD 41.636 mn. Ellis Garai is the founder of the company, with Laura Dietch serving as the CEO.BioTrace Medical Inc. specializes in innovative cardiovascular solutions, primarily focusing on its flagship product, the Tempo® Temporary Pacing Lead. Released for clinical use in advanced cardiac procedures such as Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral Valve Replacement (TMVR), the Tempo Lead ensures secure pacing for patients. Its design minimizes risks associated with traditional leads, making it a vital tool for healthcare facilities. The primary users include hospitals and cardiologists across North America, Europe, and select markets in Asia and the Middle East, targeting enhanced patient safety and faster recovery through improved pacing technology.BioTrace Medical generates revenue through direct sales of the Tempo® Temporary Pacing Lead to hospitals and healthcare providers, primarily operating in a B2B model. The sales structure revolves around partnerships with medical institutions, where clients place orders based on procedural needs, often through bulk purchasing agreements or individual contracts. The pricing reflects the lead's innovative features, supporting better patient outcomes and ensuring consistent demand.BioTrace Medical Inc. plans to leverage its recent Series B funding of USD 10.87 mn, raised in March 2021, to support its growth initiatives. The company aims to develop new products that enhance cardiac pacing technology and expand its market presence in North America, Europe, and emerging markets in Asia and the Middle East. Specific product release dates have not been disclosed, but the focus on innovation and market expansion indicates a strategic commitment to capturing new opportunities in the cardiovascular sector.

## Funding rounds

- Series A, Feb 14, 2014, $3.5M — Okapi Venture Capital

## Investors

- Okapi Venture Capital (https://capitalatlas.ai/funds/okapi-venture-capital) — Series A